Intensity Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
INTS Nasdaq 2836 intensitytherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Intensity Therapeutics, Inc.

Intensity (INTS) Q3 2026 Earnings Call Transcript - Nov 5th, 2026 3:28 pm
Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update - Nov 5th, 2026 5:45 am
Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026 - Oct 30th, 2026 6:00 am
Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting - Oct 23rd, 2026 6:00 am
Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Sep 8th, 2026 6:00 am
Intensity Therapeutics, Inc. Q2 2026 Earnings Call Summary - Aug 11th, 2026 8:22 pm
Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript - Aug 11th, 2026 7:57 pm
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Aug 11th, 2026 5:30 am
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 - Aug 4th, 2026 6:00 am
Soft Tissue Sarcoma Market Set for Significant Growth at a CAGR of 7.9% During the Forecast Period (2026-2036), Driven by Novel Therapies and Expanding Treatment Landscape | DelveInsight - Jul 15th, 2026 8:31 am
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) - Jul 15th, 2026 5:45 am
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 - Jul 1st, 2026 6:00 am
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award - May 14th, 2026 6:00 am
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 7th, 2026 2:06 pm
Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - May 1st, 2026 7:55 am
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know - Apr 16th, 2026 10:00 am
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update - Mar 27th, 2026 2:12 pm